文献速递淋巴瘤

大B细胞淋巴瘤遗留的功能异常免疫表型在治疗后持续数年

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
PubMed 文献 · Blood · 2025-01-01

研究对弥漫性大B细胞淋巴瘤(DLBCL)患者新鲜外周全血进行免疫表型全面分析,发现治疗前已存在髓源性抑制细胞增加、初始T细胞减少及活化/终末分化T细胞增多,治疗后加重;这些改变在持续完全缓解超过5年后仍存在,并与促炎标志物升高及对SARS-CoV-2特异性肽段T细胞免疫反应减弱相关。小鼠注射淋巴瘤可诱导类似T细胞改变,而乳腺癌和急性髓系白血病幸存者具有不同的免疫印记。

要点

  • DLBCL治疗前即存在髓源性抑制细胞增加、初始T细胞减少及活化/终末分化T细胞增多,治疗后加重。
  • 上述免疫改变在持续完全缓解超过5年后仍可检测到,并与白细胞介素-6、β2微球蛋白或可溶性CD14等促炎标志物升高相关。
  • 慢性炎症与针对SARS-CoV-2特异性肽段的T细胞免疫反应功能减弱相关,且反应减弱与初始T细胞减少相关。

核心结论

  • DLBCL缓解期持续存在的淋巴瘤诱导免疫改变可能解释长期并发症,对疫苗策略有启示,并可能与免疫治疗相关。

研究设计与样本

  • 研究对DLBCL患者新鲜外周全血进行免疫表型全面分析,比较治疗前与治疗后变化,并纳入乳腺癌和急性髓系白血病幸存者作为对比。
  • 采用小鼠注射淋巴瘤模型验证淋巴瘤对T细胞改变的因果关系。
  • 通过深度测序和细胞因子谱确认持续炎症,并评估针对SARS-CoV-2特异性肽段的T细胞免疫反应。

主要发现

  • 治疗前DLBCL患者外周血中髓源性抑制细胞增加、初始T细胞减少、活化和终末分化T细胞增加,治疗后上述改变加重。
  • 小鼠注射淋巴瘤后诱导类似的鼠T细胞改变,提示因果关系。
  • 乳腺癌和急性髓系白血病幸存者中观察到不同的免疫印记。
  • DLBCL患者中识别的免疫改变在持续完全缓解超过5年后仍存在,并与白细胞介素-6、β2微球蛋白或可溶性CD14等促炎标志物升高相关。
  • 慢性炎症与针对SARS-CoV-2特异性肽段的T细胞免疫反应功能减弱相关,反应减弱与初始T细胞减少相关;深度测序和细胞因子谱确认持续炎症,共同提示固有免疫的代偿性激活。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy has become standard of care in the treatment of diffuse large B-cell lymphoma (DLBCL). Changes in immunophenotypes observed at first diagnosis predict therapy outcome but little is known about the resolution of these alterations in remission. Comprehensive characterization of immune changes from fresh, peripheral whole blood revealed a functionally relevant increase of myeloid-derived suppressor cells, reduced naïve T cells, and an increase of activated and terminally differentiated T cells before treatment, which aggravated after therapy. Suggesting causal relation, injection of lymphoma in mice induced similar changes in the murine T cells. Distinct immune imprints were found in those who have survived breast cancer and acute myeloid leukemia. Identified alterations persisted beyond 5 years of ongoing complete remission and correlated with increased proinflammatory markers such as interleukin-6, β2-microglobulin, or soluble CD14 in DLBCL. The chronic inflammation was associated with functionally blunted T-cell immunity against severe acute respiratory syndrome coronavirus 2-specific peptides, and reduced responses correlated with reduced naïve T cells. Persisting inflammation was confirmed by deep sequencing and by cytokine profiles, together pointing toward a compensatory activation of innate immunity. The persisting, lymphoma-induced immune alterations in remission may explain long-term complications, have implications for vaccine strategies, and are likely relevant for immunotherapies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pelzl RJ, Benintende G, Gsottberger F, et al. Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment. Blood. 2025. PMID: 40359478. doi:10.1182/blood.2024027877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。